Anticoagulation in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy and have renal failure (February 2013)

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • As per restrictions above
  • Haemophilia recommendation only
• RNOH:
  
  • Requires Haematologist approval. See restriction above.
• UCLH:
  
  • Restricted to consultant haematologists. For patients with severe renal impairment (CrCl<30ml/min)
• WH approval:
  
  • Non-formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

• NMUH:
  
  • See links below
• RFL:
  
  • No restriction stated
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • See links below
• RFL:
  
  • No restriction stated
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

(hospital only prescribing) for defined course thromboprophylaxis and patients requiring treatment doses in line with NCL guidance (see Section 3.1)

for long-term thromboprophylaxis and patients requiring treatment doses in line with NCL guidance (see Section 3.3)

Provider notes

• NMUH:
  
  • Non-formulary
• RFL:
  
  • Prophylaxis - only whilst tinzaparin shortage
  • Treatment - haemophilia recommendation only
• RNOH:
  
  • Non-formulary
• UCLH:
• WH:
  
  • Non-formulary

(hospital only prescribing) for defined course thromboprophylaxis and patients requiring treatment doses in line with NCL guidance (see Section 3.1)

for long-term thromboprophylaxis and patients requiring treatment doses in line with NCL guidance (see Section 3.3)

Provider notes

• NMUH:
  
  • Tinzaparin is FORMULARY when used for the treatment of suspected/confirmed DVT/PE & for Thromboprophylaxis.
  • See links below
• RFL:
  
  • No restriction stated
• RNOH:
  
  • As per local guidelines
• UCLH:
• WH:
  
  • No restriction stated

Provider notes

• NMUH:
  • Non-formulary
• RFL:
  • As per local protocol only
• RNOH:
  • Non-formulary
• UCLH:
• WH:
  • Non-formulary

Provider notes

• NMUH:
  • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary but may NOT be routinely stocked in pharmacy. This medicine will be ordered if use is as per local Trust Guideline or is approved by the Trust Medicines Management Committee. Contact pharmacy medicines information on ext 2417 for further information
• RFL:
  • Non-formulary
• RNOH:
  • Restricted
• UCLH:
• WH:
  • NICE TA230 applies. Not routinely stocked at WH.

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

 Provider notes

• NMUH:
  
  • No restriction stated
• RFL:
  • No restriction stated
• RNOH:
• UCLH:
• WH:
  • No restriction stated

Approved for 

• Pulmonary hypertension (JFC November 2013).
• Approved for COVID-19 associated ARDS with refractory hypoxaemia, in line with COVID-19 Speciality guide for critical care (see JFC Position Statement).

Provider notes

• NMUH:
  
  • Restricted for ICU use only.
  • Check MHRA for Drug Safety Updates
• RFL:
  
  • Restricted to ITU and pulmonary hypertension
• RNOH:
  
  • Non-formulary
• UCLH:
  
  • Approved for primary pulmonary hypertension: functional grades III + IV
  • Approved for Inhibition of platelet aggregation during renal dialysis
• WH approvals:
  
  • No restriction stated

Provider notes

• NMUH:
  
  • Restricted to use for patients with Unstable Angina / NSTEMI.
  • See Trust Guideline on use
• RFL:
  
  • Restricted to use for patients with Unstable Angina / NSTEMI
• RNOH:
  
  • No restriction stated
• UCLH:
• WH:
  
  • Restricted for use in unstable angina and NSTMEI